• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去)

    [复制链接]
1266519 1620 老马 发表于 2011-10-27 08:05:18 | 置顶 |
老马  博士一年级 发表于 2012-4-27 18:50:42 | 显示全部楼层 来自: 浙江温州
Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
8 Y9 e. H0 T# U( `8 \& l9 I! V! sNOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9   x2 N1 g% {2 s7 _& Y. Q
+ Author Affiliations
7 I9 x* p  b7 u- k
0 k+ r  A4 e4 L1 v1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
2 `' f' ~  Q. Y/ ~/ u# ]2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan 1 o2 r0 T4 Q. m# f" W1 t1 h4 k
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
4 B1 P' y1 f  G' C0 o9 V4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
2 p2 d6 ]9 S2 E1 y5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan 3 d: G, G. u" s5 c, `% O
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan 2 C0 o" f+ {9 v4 f) F; c
7Kinki University School of Medicine, Osaka 589-8511, Japan / d/ o+ ]; O3 w* ~, i
8Izumi Municipal Hospital, Osaka 594-0071, Japan 3 b( N9 G, u+ \
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
# }" J, Y* p8 J2 xCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp
/ b+ z' U+ \) FAbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
) ]  `4 f# ]$ w
, L6 i* P5 n! }! m# ~
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:52:43 | 显示全部楼层 来自: 浙江温州
S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type
  l# \8 ^: }- I* C! K# _
( J" s. F  A/ H  r! x3 x" Y) L$ J6 [Authors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato
( R  O) P. z0 W. l/ s1 x% h" ^( X& {: X" S
Affiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  ) K6 a+ }, t5 U) W" ]; ~
% q0 j" ]7 F4 W% p8 P
Published online on: Thursday, December 1, 2011 6 d# O* f' l4 {! f
4 x6 [  L, ~% q& \: Y* u) N
Doi: 10.3892/ol.2011.507
2 Z# P% W1 [6 K0 \
7 o/ s* t; g5 J! l; e& XPages: 405-410 # W# c; o4 Q( d  N
* {1 s4 G  \6 C3 [: t3 t
Abstract:
! U' d3 Z0 t( Z9 V4 nS-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.
  I* s. p% L- |+ K2 n" H ( [$ p. f# R' v
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:57:27 | 显示全部楼层 来自: 浙江温州
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population
6 ?9 Z% |! _: O; z& dF. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3 + j/ @; I( q" N1 _" j
+ Author Affiliations
0 U7 |! A0 t( }. `7 B* ?) [. n, ]1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu
$ B; Z$ D* F+ G9 M* a2Department of Thoracic Surgery, Kyoto University, Kyoto
. N- w0 `: e0 w: p0 ?! {3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan " n5 {9 P0 w& ?; c; Y2 @! T
&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp 7 \/ m& R& g% F! _; @2 L
Received September 3, 2010. 5 o' l: B: _4 n7 G9 ?% c3 X/ R
Revision received November 11, 2010. ; i( c! R/ Z) P. s
Accepted November 17, 2010. 8 t2 V: x/ m4 I7 k8 t
Abstract
+ l3 T9 Q% s) R4 `2 u5 ^Background: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed.
5 I7 ^: d, _5 I) d  L. n; GPatients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes.
2 l* F7 G/ A# vResults: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression.
4 s" o9 {( M! u% ?Conclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study. 8 u( q6 S6 l. J
个人公众号:treeofhope
走在异乡  高中一年级 发表于 2012-4-28 00:30:22 | 显示全部楼层 来自: 四川成都
一直关注老马的帖子,前方的指明灯。祝福你爸好疗效
累计签到:1 天
连续签到:1 天
[LV.1]初来乍到
baiselianyi  初中二年级 发表于 2012-4-28 10:24:44 | 显示全部楼层 来自: 浙江台州
一直得到老马帮助,祝福老马爸爸
老马  博士一年级 发表于 2012-4-28 18:00:37 | 显示全部楼层 来自: 浙江温州
26日吃了12片地米(0.75mg一片),27日吃了22片地米(0.75mg 一片),28日吃了12片地米(0.75mg一片),都分二次吃。
8 k4 G! P0 I% J今天为止没有任何反应,每天吃VC,VB2,还有漱口水,就怕口腔溃疡。
个人公众号:treeofhope
bishop_cn  大学一年级 发表于 2012-4-28 23:16:11 | 显示全部楼层 来自: 中国
副作用如何,单药反应很小吧?% k7 `9 t$ g9 S4 ?6 O8 i/ f
老马  博士一年级 发表于 2012-4-29 00:20:00 | 显示全部楼层 来自: 浙江温州
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy
7 m+ f8 k4 t  yhttp://clinicaltrials.gov/ct2/show/NCT01523587
& @! c: J% ?& F/ {5 z; \. ]1 z
$ Z. ?: O3 m; w0 Q4 FBIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC& f1 d( l! e3 Q* r
http://clinicaltrials.gov/ct2/show/NCT01156545
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-29 20:53:58 | 显示全部楼层 来自: 浙江温州
本帖最后由 老马 于 2012-4-30 09:33 编辑 & I7 c2 b. V! ^7 h- _

9 k% T4 h$ G6 Z: Z6 D从4月24日开始到4月28日,打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
- o* U# |$ m# P至今为止,未出现化疗副作用。
个人公众号:treeofhope
英雄武松  大学四年级 发表于 2012-4-30 01:37:05 | 显示全部楼层 来自: 哈萨克斯坦
老马 发表于 2012-4-29 20:53
& o8 Q3 t- ?4 E3 B( Q8 g0 _0 W& g从4月24日开始到4月28日,打了5天的打了5天舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。/ c7 F2 [5 ?$ |$ I" i
至今为止,未出 ...

. L$ ^6 ?1 m: o+ [没有副作用是第一追求,效果显著是第二追求。& G$ f4 G8 J1 v9 {
不错。

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表